Stress Urinary Incontinence in Women

2

Review clinical trials related to Stress Urinary Incontinence in Women. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

The AMPER Study: Evaluation of the Efficacy of Human Amniotic Membrane Grafting in Preventing Mesh Exposure in Vaginal Reconstructive Surgery Using Polypropylene Mesh.

This study evaluates the efficacy of adding a human amniotic membrane graft to polypropylene mesh surgery for pelvic prolapse and stress urinary incontinence. The goal is to assess improvements in tissue integration and the reduction of surgical complications

Participants needed: 330
Trial details
Biological sex: FemaleType: InterventionalSponsor: Hospital General de Agudos J. M. PennaUpdated: Jun 17, 2026Locations: 1
Eligibility criteria

Pelvic organ prolapse (POP) stage II C or greater, defined as C ≥ +1, in women w... [+2]

Previous surgery with synthetic mesh (via vaginal or abdominal approach) for POP... [+5]

Status: Not yet recruiting

Treated Umbilical Vein Allograft (UVT) Versus Autologous Fascial Pubovaginal Sling in the Treatment of Female Stress Urinary Incontinence

The goal of this clinical trial is to evaluate whether a treated umbilical vein allograft is effective in treating stress urinary incontinence in females. The researchers will compare the treated umbilical vein allograft with a sling made of autologous tissue. The main question the clinical trial aims to answer is: \- Is the treated umbilical vein allograft as effective as the sling made of autologous tissue for treating female stress urinary incontinence? Participants will: * Undergo surgical treatment with either the umbilical vein allograft or the sling made of autologous tissue on Day 0. * Visit the hospital for a series of tests at 3 weeks, 3 months, 6 months, and 12 months after the surgical intervention. * Record their bladder activity between each hospital visit.

Participants needed: 96
Trial details
Phase: Phase 3Age: 18-85Biological sex: FemaleType: InterventionalSponsor: TBF Genie TissulaireUpdated: Sep 30, 2025Locations: 8
Eligibility criteria

Women aged 18 to 85 years. [+8]

Pregnant or breastfeeding women or those not using effective contraception. [+11]